Research output per year
Research output per year
Personal profile
Research Interests
Anti-cancer therapeutics
Neuro oncology
Gynaecological cancers
Genitourinary cancers
Rare cancers - cancer of unknown primary, endocrine cancers and others
Supportive care
Neuro oncology
Gynaecological cancers
Genitourinary cancers
Rare cancers - cancer of unknown primary, endocrine cancers and others
Supportive care
Research Expertise
Cancer
Cancer Pharmacology
Education/Academic qualification
PhD, Flinders University
External positions
Clinical lead, Statewide Cancer Clinical Network, Commission on Excellence and Innovation in Health (CEIH)
2019 → …
SALHN, Southern Adelaide Local Health Network
Fingerprint
Dive into the research topics where Ganessan Kichenadasse is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study
Agar, M. R., Nowak, A. K., Hovey, E. J., Barnes, E. H., Simes, J., Vardy, J. L., Wheeler, H. R., Kong, B. Y., Leonard, R., Hall, M., Tim, E., Spyridopoulos, D., Sim, H. W., Lwin, Z., Dowling, A., Harrup, R., Jennens, R., Kichenadasse, G., Dunlop, T., Gzell, C., & 1 others, Sept 2023, In: BMJ Supportive and Palliative Care. 13, 3, p. 354-362 9 p.Research output: Contribution to journal › Article › peer-review
-
Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
Hopkins, A. M., Logan, J. M., Kichenadasse, G. & Sorich, M. J., Apr 2023, In: JNCI Cancer Spectrum. 7, 2, 3 p., pkad010.Research output: Contribution to journal › Review article › peer-review
Open AccessFile3 Citations (Scopus)4 Downloads (Pure) -
ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study
Lemech, C. R., Kichenadasse, G., Marschner, J. P., Alevizopoulos, K., Otterlei, M. & Millward, M., 10 Feb 2023, In: Oncogene. 42, 7, p. 541-544 4 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)4 Downloads (Pure) -
Current and emerging medications for the management of obesity in adults
Inglis, J. M., Kichenadasse, G. & Mangoni, A. A., Aug 2023, In: Medical Journal of Australia. 219, 4, p. 187 1 p.Research output: Contribution to journal › Letter › peer-review
2 Citations (Scopus) -
Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges
van Leuven, J., Evans, S., Kichenadasse, G., Steeghs, N., Bonevski, B., Mikus, G. & van Dyk, M., 1 Jul 2023, In: Cancers. 15, 13, 11 p., 3293.Research output: Contribution to journal › Article › peer-review
Open AccessFile
Activities
- 1 Oral presentation
-
Utility of a self-management approach in lifestyle interventions for cancer survivors - preliminary findings from the NAPA trial
Sharon Lawn (Speaker), Stephanie Zrim (Speaker), Stephanie Leggett (Speaker), Michelle Miller (Speaker), L Jones (Speaker), Jim Dollman (Speaker), Sue Booth (Speaker), Richard Woodman (Speaker), Chris Karapetis (Speaker), Ganessan Kichenadasse (Speaker), Shawgi Sukumaran (Speaker) & Bogda Koczwara (Speaker)
6 Feb 2013Activity: Talk or presentation types › Oral presentation